Complete or partial remission · adults with FSGS
Cyclosporin may leads to higher complete or partial remission compared with different comparators (low certainty).
1 finding from 1 review
Chronic kidney disease · adults with FSGS
Cyclosporin showed no clear difference in chronic kidney disease compared with different comparators (low certainty).
1 finding from 1 review
Kidney failure · adults with FSGS
Cyclosporin showed no clear difference in kidney failure compared with different comparators (low certainty).
1 finding from 1 review
Adverse events: hypertension · adults with FSGS
1 finding from 1 review
Adverse effects: infection · adults with FSGS
1 finding from 1 review
PE: assessed by CT arteriography ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in PE: assessed by CT arteriography ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).
1 finding from 1 review
Asymptomatic DVT · adults undergoing KA
It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).
1 finding from 1 review
All‐cause mortality ( · adults undergoing KA
1 finding from 1 review
All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Duration of bleeding Total bleeding in 90 days (bleeding calendar)
1 finding from 1 review
Menstrual blood loss PBAC score
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea
Mefanamic acid showed no clear difference in side effects: nausea compared with vitex agnus; GRADE not reported.
1 finding from 1 review
OR 1 [0.06, 16.53]
1 participants
GRADE not reported
Abdominal pain
Mefanamic acid showed no clear difference in side effects: abdominal pain compared with vitex agnus; GRADE not reported.
1 finding from 1 review
OR 0.33 [0.01, 8.22]
0 participants
GRADE not reported
Pelvic pain
It is very uncertain whether tranexamic acid changes pelvic pain compared with sodium diclofenac (very low certainty).
1 finding from 1 review
Naproxen vs placebo
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale)
1 finding from 1 review